Core Viewpoint - The company reported a revenue of 1.05 billion yuan for the first half of 2025, marking a year-on-year growth of 7.99%. Despite a short-term net loss due to increased R&D expenses, breakthroughs in ADC drugs and mRNA vaccines are opening up significant growth opportunities in the biopharmaceutical industry [1] Group 1: Financial Performance - The company achieved a revenue of 1.05 billion yuan in the first half of 2025, reflecting a year-on-year increase of 7.99% [1] - The net profit was impacted by a surge in R&D expenses, leading to a temporary loss [1] Group 2: R&D and Innovation - R&D investment reached 455 million yuan, representing a substantial year-on-year increase of 80.81%, accounting for 43% of total revenue [4] - The company has established multiple differentiated technology platforms, including antibody engineering and ADC technology platforms, to meet diverse biopharmaceutical R&D needs [5] Group 3: Product Development and Market Position - The company’s subsidiary, Jushi Biopharma, made significant progress in commercializing key products, including the approval of Enyitan for treating moderate to severe persistent allergic asthma [2] - The company is actively expanding its product offerings in functional foods and raw materials, achieving sales revenue of 934 million yuan in this segment, remaining stable compared to the previous year [3] Group 4: International Collaboration - A strategic partnership was formed with Radiance Biopharma, granting exclusive rights for the development and commercialization of SYS6005 in major markets, with a total transaction value of up to 1.24 billion USD [2] Group 5: Clinical Trials and Regulatory Approvals - Several in-development products are at critical stages, with Ustinumab injection submitted for market approval and others in key clinical trial phases [6] - The company received multiple clinical trial approvals from the FDA, enhancing its global development capabilities [6]

每经AI快讯，新诺威（SZ 300765，收盘价：53元）8月15日晚间发布公告称，公司第六届第二十五次董 事会会议于2025年8月14日在公司会议室以现场加通讯表决相结合的方式召开。会议审议了《关于公司 <2025年半年度报告>及其摘要的议案》等文件。 2024年1至12月份，新诺威的营业收入构成为：功能食品及原料行业占比92.91%，生物制药行业占比 4.43%，其他业务占比2.66%。 截至发稿，新诺威市值为744亿元。 每经头条（nbdtoutiao）——华康股份11亿元并购疑云：收购对象的大客户两年前已深陷债务危机，如 何贡献巨额营收？ （记者 曾健辉） ...

星标 ★ IPO日报 精彩文章第一时间推送 4月28日晚间，石药创新制药股份有限公司（下称"新诺威"，300765.SZ）发布公告称，公司于4月28日召开第六届董事会第二十四次会议、第六 届监事会第十九次会议，审议通过了《关于终止发行股份及支付现金购买资产并募集配套资金暨关联交易事项并撤回申请文件的议案》，同意公司 终止发行股份及支付现金购买资产并募集配套资金暨关联交易事项并撤回申请文件。 新诺威表示，鉴于本次重组事项自筹划以来已历时较长，医药行业及资本市场整体环境等情况较本次重组筹划之初发生了一定变化，为维护公司全体股东 长期利益，经公司与交易各相关方友好协商、认真研究和充分论证，基于审慎性考虑，决定终止本次重组事项。 受此消息影响，4月29日，新诺威低开13.21%，开盘价为35.66元/股。截至今日收盘，新诺威报39.6元/股，跌幅为3.63%。 来源：张力 筹划一年多 回顾本次收购，公司最早在2024年1月宣布了并购消息。2024年12月，深交所受理了公司的并购重组申请，并在同月下发了问询函。2025年1月，公司回复 了问询函。2025年3月，因相关财务资料已过有效期需要补充提交，深交所对本次交易中止 ...

Core Viewpoint - The company, Shiyao Innovation Pharmaceutical Co., Ltd. (New Nuo Wei), has decided to terminate its planned acquisition of 100% equity in Shiyao Group Baike (Shandong) Biopharmaceutical Co., Ltd. due to changes in the pharmaceutical industry and capital market environment since the initial planning of the transaction [1][5][6]. Group 1: Acquisition Details - The acquisition was initially announced in January 2024, with the Shenzhen Stock Exchange accepting the application in December 2024 [4]. - The intended transaction price for the acquisition was 7.6 billion yuan, with an additional 1.78 billion yuan planned for fundraising to support cash payments and various projects [5]. - The target company, Shiyao Baike, specializes in the development and commercialization of innovative biopharmaceuticals, particularly long-acting protein drugs [5][6]. Group 2: Financial Performance - Shiyao Baike reported revenues of 2.235 billion yuan, 2.316 billion yuan, and 922 million yuan for the years 2022, 2023, and the first half of 2024, respectively, with net profits of 620.96 million yuan, 784.97 million yuan, and 390.38 million yuan [6]. - The valuation of Shiyao Baike was assessed at 7.62 billion yuan, reflecting a 78.25% increase over its book net assets [6]. - The company noted a decline in revenue and net profit for the first half of 2024, attributed to the impact of provincial alliance procurement policies on the sales of its main product, Jinyouli [6]. Group 3: Company Background and Market Position - New Nuo Wei is a subsidiary of Shiyao Group, which was established in 2006 and has undergone multiple acquisitions of assets from Shiyao Group since its listing [8]. - The company primarily operates in the functional raw materials and health food sectors, with revenues from these areas accounting for 93% of its total income in 2024 [12]. - Despite entering the biopharmaceutical sector, the revenue from this segment remains minimal, contributing less than 5% to total revenue [12].